Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon

Antiviral Research

Volumn 102, Issue , 2014, Pages 35-43

  Boglione, Lucio ^a   Cusato, Jessica ^a   Allegra, Sarah ^a   Esposito, Isabella ^a   Patti, Francesca ^a   Cariti, Giuseppe ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

HBeAg negative; HBV genotype; Hepatitis B; IL28 B; PEG IFN; Predictive factor

Indexed keywords

HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CCCDNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS E ANTIGEN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON; RECOMBINANT PROTEIN; SODIUM;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BIOCHEMISTRY; DNA POLYMORPHISM; ETHNICITY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIROLOGY; VIRUS LOAD; YOUNG ADULT; ALT; BLOOD; CHB; CHRONIC HEPATITIS B; CLASSIFICATION; CLOSED CIRCULAR DNA; GENETIC POLYMORPHISM; GENETICS; HBEAG-NEGATIVE; HBV GENOTYPE; HCC; IL28-B; INTER-QUARTILE RANGE; IQR; LIVER CELL CARCINOMA; NUCLEOS(T)IDE ANALOGUES; PEG-IFN; PEG-INF; PREDICTIVE FACTOR; QHBSAG; QUANTITATIVE HBSAG; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SUSTAINED VIROLOGICAL RESPONSE; SVR; TREATMENT OUTCOME; UNL; UPPER NORMAL LEVEL; PROTEIN FUNCTION;

ALANINE AMINOTRANSFERASE; ALT; CCCDNA; CHB; CHRONIC HEPATITIS B; CLOSED CIRCULAR DNA; HBEAG; HBEAG-NEGATIVE; HBSAG; HBV; HBV GENOTYPE; HCC; HEPATITIS B; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; HEPATITIS E ANTIGEN; HEPATOCELLULAR CARCINOMA; IL28-B; INTER-QUARTILE RANGE; IQR; NA; NUCLEOS(T)IDE ANALOGUES; PEG-IFN; PEG-INF; PEGYLATED INTERFERON; PREDICTIVE FACTOR; QHBSAG; QUANTITATIVE HBSAG; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SUSTAINED VIROLOGICAL RESPONSE; SVR; UNL; UPPER NORMAL LEVEL;

ADULT; ANTIVIRAL AGENTS; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84892855955     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.11.014     Document Type: Article

References (37)

1. Balagopal A., Thomas D.L., Thio C.L. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010, 139:1865-1876.
2. Boglione L., D'Avolio A., Cariti G., Milia M.G., Simiele M., De Nicolò A., Ghisetti V., Di Perri G. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J. Viral. Hepat. 2013, 20:e11-e19.
3. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., Piratvisuth T., Luo K., Wang Y., Hadziyannis S., Wolf E., McCloud P., Batrla R., Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
4. Chen J., Wang L., Li Y., Cai B., Fu Y., Liao Y., Zhang J. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One 2012, 7:e50787.
5. D'Avolio A., Ciancio A., Siccardi M., Baietto L., Simiele M., Cariti G., Calcagno A., Smedile A., Cusato J., Bonora S., Rizzetto M., Di Perri G. Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. Hepatology 2011, 54:2278-2279.
6. D'Avolio A., Ciancio A., Siccardi M., Smedile A., Simiele M., Cusato J., Baietto L., Marucco D.A., Cariti G., Calcagno A., Gonzalez de Requena D., Sciandra M., Troshina G., Caviglia G.P., Bonora S., Rizzetto M., Di Perri G. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Ther. Drug Monit. 2012, 34:722-728.
7. de Niet A., Takkenberg R.B., Benayed R., Riley-Gillis B., Weegink C.J., Zaaijer H.L., Koot M., Jansen P.L., Beld M.G., Lopatin U., Reesink H.W. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand. J. Gastroenterol. 2013, 47:475-481.
8. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50:227-242. EASL.
9. Feld J.J., Wong D.K., Heathcote E.J. Endpoints of therapy in chronic hepatitis B. Hepatology 2009, 49:S96-S102.
10. Flink H.J., van Zonneveld M., Hansen B.E., de Man R.A., Schalm S.W., Janssen H.L. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol. 2006, 101:297-303.
11. Fung S.K., Lok A.S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?. Hepatology 2004, 40:790-792.
12. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
13. Holmes J.A., Nguyen T., Ratnam D., Heerasing N.M., Tehan J.V., Bonanzinga S., Dev A., Bell S., Pianko S., Chen R., Visvanathan K., Hammond R., Iser D., Rusli F., Sievert W., Desmond P.V., Bowden D.S., Thompson A.J. IL28B genotype is not useful for predicting treatment outcome in asian chronic hepatitis b patients treated with pegylated-interferon-alpha. J. Gastroenterol. Hepatol. 2013.
14. Holmes J.A., Nguyen T., Ratnam D., Heerasing N.M., Tehan J.V., Bonanzinga S., Dev A., Bell S., Pianko S., Chen R., Visvanathan K., Hammond R., Iser D., Rusli F., Sievert W., Desmond P.V., Bowden D.S., Thompson A.J. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. J. Gastroenterol. Hepatol. 2013, 28:861-866.
15. Kim S.U., Song K.J., Chang H.Y., Shin E.C., Park J.Y., Kim do Y., Han K.H., Chon C.Y., Ahn S.H. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS One 2013, 8:e69166.
16. Lampertico P., Vigano M., Cheroni C., Facchetti F., Invernizzi F., Valveri V., Soffredini R., Abrignani S., De Francesco R., Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896.
17. Lee D.H., Cho Y., Seo J.Y., Kwon J.H., Cho E.J., Jang E.S., Kwak M.S., Cheong J.Y., Cho S.W., Lee J.H., Yu S.J., Yoon J.H., Lee H.S., Kim C.Y., Shin H.D., Kim Y.J. Polymorphisms near interleukin 28B gene are not associated with hepatitis B virus clearance, hepatitis B e antigen clearance and hepatocellular carcinoma occurrence. Intervirology 2013, 56:84-90.
18. Lee I.C., Lin C.H., Huang Y.H., Huo T.I., Su C.W., Hou M.C., Huang H.C., Lee K.C., Chan C.C., Lin M.W., Lin H.C., Lee S.D. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One 2013, 8:e58071.
19. Lin C.L., Kao J.H. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 2011, 26(Suppl. 1):123-130.
20. Locarnini S. Molecular virology of hepatitis B virus. Semin. Liver Dis. 2004, 24(Suppl. 1):3-10.
21. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
22. Martin M.P., Qi Y., Goedert J.J., Hussain S.K., Kirk G.D., Hoots W.K., Buchbinder S., Carrington M., Thio C.L. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J. Infect. Dis. 2010, 202:1749-1753.
23. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Gunthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. (1345 e1331-1337).
24. Rijckborst V., Hansen B.E., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., Simon K., Akarca U.S., Flisiak R., Verhey E., Van Vuuren A.J., Boucher C.A., ter Borg M.J., Janssen H.L. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010, 52:454-461.
25. Seto W.K., Wong D.K., Kopaniszen M., Proitsi P., Sham P.C., Hung I.F., Fung J., Lai C.L., Yuen M.F. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin. Infect. Dis. 2013, 56:1695-1703.
26. Sonneveld M.J., Rijckborst V., Boucher C.A., Hansen B.E., Janssen H.L. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52:1251-1257.
27. Sonneveld M.J., Wong V.W., Woltman A.M., Wong G.L., Cakaloglu Y., Zeuzem S., Buster E.H., Uitterlinden A.G., Hansen B.E., Chan H.L., Janssen H.L. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142(513-520):e511.
28. Sonneveld M.J., Wong V.W.S., Woltman A.M., Wong G.L.H., Buster E.H.C.J., Hansen B.E., Chan H.L.Y., Janssen H.L.A. polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (peg-)interferon in Hbeag-positive chronic hepatitis B. J. Hepatol. 2012, 54:S32. (S32).
29. Sonneveld M.J., Brouwer W.P., Janssen H.L. Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. Hepatology 2013, 57:1283.
30. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
31. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
32. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
33. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R., Poordad F., Lawitz E.J., McCone J., Shiffman M.L., Galler G.W., Lee W.M., Reindollar R., King J.W., Kwo P.Y., Ghalib R.H., Freilich B., Nyberg L.M., Zeuzem S., Poynard T., Vock D.M., Pieper K.S., Patel K., Tillmann H.L., Noviello S., Koury K., Pedicone L.D., Brass C.A., Albrecht J.K., Goldstein D.B., McHutchison J.G. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(120-129):e118.
34. Urban S., Schulze A., Dandri M., Petersen J. The replication cycle of hepatitis B virus. J. Hepatol. 2010, 52:282-284.
35. WHO, 2013. Hepatitis B, fact sheet n. 204, In: Organization, W.H. (Ed.), WHO | Hepatitis B, World Health Organization.
36. Wong S.N., Lok A.S. Treatment of hepatitis B: who, when, and how?. Arch. Intern. Med. 2006, 166:9-12.
37. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 1993, 119:312-323.